Osmotica Pharmaceutical Corp. Announces the Appointment of Gene Wright,
Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development
WILMINGTON, N.C. & MARIETTA, Ga. -- September 6, 2013
Osmotica Pharmaceutical Corp. today announced the appointment of Gene Wright,
Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development. In his
role, Dr. Wright will serve as a key member of the senior leadership team at
Osmotica Pharmaceutical, where he is responsible for leading the global
clinical development strategy and execution for the company’s development
programs. Praveen Tyle, Ph.D., President and CEO of Osmotica Pharmaceutical
stated, “We are very pleased to have Gene as part of our senior leadership
team. Gene will play an integral role in the success of our organization as we
continue to bring innovated products to the marketplace, especially as we
devote more resources towards novel drug development programs.”
Dr. Wright has over 25 years of pharmaceutical industry experience in early
and late stage global clinical development programs in CNS, pain, rheumatoid
arthritis and infectious disease. Prior to joining Osmotica Pharmaceutical, he
was Senior Vice President of Clinical Development at Zalicus Inc., which was
formed through the merger of CombinatoRx, Inc. and Neuromed Pharmaceuticals.
At Zalicus, he was responsible for the development programs in pain and
inflammation. Prior to joining Neuromed, Dr. Wright worked for Schering-Plough
Corporation as Executive Director and Senior Project Leader of the
Antiviral/Antifungal groups. He also worked as Vice President of CNS/Pain
Development, Project Management and Pharmacokinetics at Biovail Technologies
and at Pharmacia.
Dr. Wright earned his doctor of pharmacy from the University of the Pacific in
Stockton, CA, master’s degree in business administration from National
University in San Diego and a doctor of philosophy in Pharmaceutical Sciences
from the University of Kentucky.
About Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company with a
proven history of developing commercially successful pharmaceutical products.
The company uses its proprietary osmotic technology platform and with
strategic partners develops and commercializes high quality pharmaceutical
products. In addition to the products currently on the market, the company’s
pipeline includes numerous ANDA programs and several innovative
neurology-based NDA programs.
Osmotica Pharmaceutical and its related companies form an international group
of companies with principal operations located in the United States, Argentina
For more information on the Company, please visit Osmotica’s website at
www.osmotica.com. This press release is directed to residents of the United
Osmotica Pharmaceutical Corp.
Al Cavagnaro, 910-509-0114 ext. 1005
Press spacebar to pause and continue. Press esc to stop.